Pfizer (NYSE:PFE) has initiated Phase 3 clinical trials on vaccine candidates for preventing pneumonia, RSV and meningitis.
20-valent pneumococcal vaccine (20vPnC): Two studies, NCT04382326 and NCT04379713, will assess a four-dose series in healthy infants. The former is aimed at determining immunologic non-inferiority to Prevnar 13.
RSV vaccine (RSVpreF): Study NCT04424316 is assessing the vaccine in infants born to immunized women.
Pentavalent meningococcal vaccine (MenABCWY): Study NCT04440163 is assessing the vaccine in adolescents and young adults aimed at determining non-inferiority to licensed vaccines.
